Charleroi

• A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal … Recruiting
  2023-507097-41-01 5 2025-03-20 Patients with limited-stage small cell lung cancer (LS-SCLC) without
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 10 2024-10-02 Locally advanced or metastatic urothelial cancer
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• Safety and effect of mesenchymal derived Extracellular Vesicles in the prevention of Bronchopulmonary Dysplasia in extremely preterm newborn … Recruiting
  2022-500293-34-01 7 2023-12-28 Bronchopulmonary Dysplasia
• A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati … Recruiting
  2022-502959-54-00 5 2023-09-26 Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Ep
• A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors Recruiting
  2022-502654-14-00 4 2023-09-11 Endometrial cancer
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A prospective multicentre single-arm study in adults to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant … Recruiting
  2024-517762-42-01 7 2018-08-02 recalcitrant lower limb nonunion
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination with Atezolizumab … Recruiting
  2024-517490-24-00 4 2026-03-31 Small Cell Lung Cancer
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting
  2025-522873-12-00 5 2026-02-24 ER+, HER2- Advanced Breast Cancer
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Ad … Recruiting
  2025-521124-29-00 10 2026-02-13 Non-Small Cell Lung Cancer
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• A randomized, double-blind, placebo-controlled, multicentre trial, assessing the impact of ferric carboxymaltose on exercise capacity and fu … Recruiting
  2025-522936-14-00 6 2026-01-27 Pulmonary hypertension
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adoles … Recruiting
  2024-518156-24-00 5 2025-11-10 Atopic Dermatitis
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca

Showing 25–48 of 205 trials